[Summary of second-line treatment of stage IV NSCLC without oncogenic addiction].

Abstract excerpt

Stage IV non-small cell lung cancer (NSCLC) without actionable mutations remains a major therapeutic challenge, especially following immunotherapy failure. The introduction of immune checkpoint inhibitors (anti-PD-1/PD-L1) has revolutionized first-line treatment, but second-line options remain largely dependent on older chemotherapies such as docetaxel or pemetrexed. A significant number of patients experience...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Vaccines
• Share to Docetaxel
• Share to Drug Resistance, Neoplasm